[{"id":"04dc5f85-501f-4bef-9699-930885ac6468","acronym":"PACIFIC-8","url":"https://clinicaltrials.gov/study/NCT05211895","created_at":"2022-01-29T18:05:07.133Z","updated_at":"2025-02-25T14:02:42.829Z","phase":"Phase 3","brief_title":"A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC","source_id_and_acronym":"NCT05211895 - PACIFIC-8","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" EGFR wild-type • ALK wild-type","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • domvanalimab (AB154)"],"overall_status":"Recruiting","enrollment":" Enrollment 860","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 06/27/2028","primary_completion_date":" 06/27/2028","study_txt":" Completion: 08/30/2030","study_completion_date":" 08/30/2030","last_update_posted":"2025-02-19"},{"id":"4f7b2be7-d23d-40b8-a5c9-76b1850fdede","acronym":"","url":"https://clinicaltrials.gov/study/NCT04736173","created_at":"2021-02-03T16:02:06.319Z","updated_at":"2024-07-02T16:34:37.611Z","phase":"Phase 3","brief_title":"Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04736173","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154) • mitazalimab (ADC-1013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 02/08/2021","start_date":" 02/08/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-06"},{"id":"6bb1edff-f3e6-46a7-a9e0-e5a2bfe3f8ab","acronym":"EDGE-Gastric","url":"https://clinicaltrials.gov/study/NCT05329766","created_at":"2023-01-23T16:59:58.940Z","updated_at":"2024-07-02T16:34:38.031Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","source_id_and_acronym":"NCT05329766 - EDGE-Gastric","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154) • quemliclustat (AB680)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 06/10/2022","start_date":" 06/10/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-05"},{"id":"607d2950-c677-467b-8196-ea2b0e2b9d8e","acronym":"VELOCITY-Lung","url":"https://clinicaltrials.gov/study/NCT05633667","created_at":"2022-12-01T15:57:15.119Z","updated_at":"2024-07-02T16:34:58.933Z","phase":"Phase 2","brief_title":"Study of Novel Treatment Combinations in Patients With Lung Cancer","source_id_and_acronym":"NCT05633667 - VELOCITY-Lung","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • PD-L1 • ALK","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154) • etrumadenant (AB928)"],"overall_status":"Recruiting","enrollment":" Enrollment 397","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-04"},{"id":"15f2feeb-91bd-4d1e-8210-eb0dea4872da","acronym":"ARC-7","url":"https://clinicaltrials.gov/study/NCT04262856","created_at":"2021-01-18T20:42:57.527Z","updated_at":"2024-07-02T16:35:00.997Z","phase":"Phase 2","brief_title":"Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04262856 - ARC-7","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928) • mitazalimab (ADC-1013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-24"},{"id":"0a6115e7-c012-4d05-b47c-86e7c080cae9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05130177","created_at":"2021-11-23T14:53:41.387Z","updated_at":"2024-07-02T16:35:05.811Z","phase":"Phase 2","brief_title":"Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma","source_id_and_acronym":"NCT05130177","lead_sponsor":"Diwakar Davar","biomarkers":" BRAF • CTLA4","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 03/16/2022","start_date":" 03/16/2022","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2024-05-06"},{"id":"1cb5fcda-fc0d-47da-bc21-1ef95536ae56","acronym":"STAR-121","url":"https://clinicaltrials.gov/study/NCT05502237","created_at":"2022-08-16T11:56:10.218Z","updated_at":"2024-07-02T16:35:06.556Z","phase":"Phase 3","brief_title":"Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05502237 - STAR-121","lead_sponsor":"Gilead Sciences","biomarkers":" EGFR • BRAF • ALK • RET • NTRK","pipe":" | ","alterations":" BRAF mutation • ALK mutation • RET mutation","tags":["EGFR • BRAF • ALK • RET • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ALK mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-05-01"},{"id":"f5b1a6c8-e4d4-430b-b708-74c9cb48dc4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04791839","created_at":"2021-03-10T12:55:03.832Z","updated_at":"2024-07-02T16:35:10.680Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04791839","lead_sponsor":"Washington University School of Medicine","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/04/2021","start_date":" 08/04/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2024-04-09"},{"id":"491d898f-8337-422d-865b-11073ce2b8d3","acronym":"ZODIAC","url":"https://clinicaltrials.gov/study/NCT06250036","created_at":"2024-02-08T19:21:26.261Z","updated_at":"2024-07-02T16:35:20.138Z","phase":"Phase 2","brief_title":"Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC)","source_id_and_acronym":"NCT06250036 - ZODIAC","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2031","study_completion_date":" 09/01/2031","last_update_posted":"2024-02-08"}]